The FDA has handed Ocular Therapeutix Inc (NASDAQ:OCUL) a Form 483 detailing observations made during the second review of the manufacturing site by a …
BTIG analyst Dane Leone weighs in on Ocular Therapeutix Inc (NASDAQ:OCUL), following the news that CFO Bradford Smith will step down from his position as …
Immunomedics, Inc. Immunomedics, Inc.
This morning, Ocular Therapeutix Inc (NASDAQ:OCUL) announced the resubmission of a New Drug Application (NDA) to the FDA for Dextenza, a drug-device combination for …
Ocular Therapeutix Inc (NASDAQ:OCUL) shares popped nearly 14% yesterday, after the biopharmaceutical company announced a $10 million drug development deal with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) …
Ocular Therapeutix Inc (NASDAQ:OCUL) shares fell more than 50% on Friday, after the company’s most advanced asset, a sustained-release formulation of the anti-inflammatory dexamethasone (branded as …
